

December 5, 2024

To the Press and Interested Parties

TOWA PHARMACEUTICAL CO., LTD.

## **Listing of New Products (New Generics) in the NHI Drug Price Standard**

Towa Pharmaceutical Co., Ltd. (Head office: Kadoma, Osaka; President and Representative Director: Itsuro Yoshida; hereinafter, the “Company”) announces that it will start selling new products (new generics) sequentially from December 6, the effective date of their listing in the NHI Drug Price Standard, following public notice in the official gazette on December 5.

As a result, the number of the Company’s products will be 326 ingredients and 759 items.

### **1. RIVAROXABAN OD TABLETS**

Product name	RIVAROXABAN OD TABLETS 10mg “TOWA” / OD TABLETS 15mg “TOWA”
Brand-name drugs	Xarelto OD tablets 15mg

### **2. VILDAGLIPTIN TABLETS**

Product name	VILDAGLIPTIN TABLETS 50mg “TOWA”
Brand-name drugs	Equa Tablets 50mg

### **3. LENALIDOMIDE CAPSULES**

Product name	LENALIDOMIDE CAPSULES 2.5mg “TOWA” / CAPSULES 5mg “TOWA”
Brand-name drugs	Revlimid Capsules 2.5mg

### **4. SUGAMMADEX INTRAVENOUS SOLUTION**

Product name	SUGAMMADEX INTRAVENOUS SOLUTION 200mg “TOWA” / INTRAVENOUS SOLUTION 500mg “TOWA”
Brand-name drugs	BRIDION Intravenous 200mg / 500mg

## 5. SUMATRIPTAN TABLETS

Product name	SUMATRIPTAN TABLETS 50mg “TW”
Brand-name drugs	IMIGRAN Tablets 50

## 6. LOXOPROFEN SODIUM TAPE

Product name	LOXOPROFEN SODIUM TAPE 50mg “TW”/ TAPE 100mg “TW”
Brand-name drugs	LOXONIN TAPE 100mg

## 7. PEMETREXED INTRAVENOUS INFUSION

Product name	PEMETREXED INTRAVENOUS INFUSION 800mg “TOWA”*
Brand-name drugs	Alimta Injection 100mg / 500mg (Different dosage forms and contents)

\*PEMETREXED INTRAVENOUS INFUSION 800mg “TOWA”, for which manufacturing and marketing approval has been obtained by FUJIFILM Toyama Chemical Co., Ltd., will be exclusively distributed by Towa Pharmaceutical.

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

### [Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Tel: +81-6-6900-9102 / Email: [kouhou@towayakuhin.co.jp](mailto:kouhou@towayakuhin.co.jp)